Sickle cell disease/disorder(s); Thalassemia; Incidence; Europe
Abstract :
[en] An estimation of the incidence and demographic picture of the major haemoglobinopathies in Belgium has been approached through a confidential inquiry sent to 228 haematological departments. Forty two percent of responses have shown that 417 patients are known in Belgium: 83% with sickle cell disease, 13% with -thalassaemia major, 2% with -thalassaemia intermedia, and 1% with haemoglobin H disease. Twenty five percent of the sickle cell disease patients and 54% of those suffering from a -thalassaemia major were older than 20 years. Three hospitals insure the follow-up of 70% of the patients and are situated in Brussels; in 21 centres a follow-up of less than 20 patients was reported. Those results confirm that sickle cell disease is the first major haemoglobinopathy in Belgium; it concerns mostly paediatricians but adult haematologists are also confronted with those pathologies. Therefore, it is necessary to implement integrated programs of prevention and treatment.
Disciplines :
Hematology
Author, co-author :
GULBIS, B
FERSTER, A
VERMYLEN, C
DRESSE, Marie-Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Service de pédiatrie (CHR)
VANDERFAEILLIE, A
DELANNOY, A
LABARQUE, V
PHILIPPET, P
KENTOS, A
SZTERN, B
DE PRIJCK, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie clinique
VERTONGEN, F
Language :
English
Title :
An estimation of the incidence and demographic picture of the major hemoglobinopathies in Belgium (from a confidential inquiry)
Publication date :
2008
Journal title :
Hemoglobin
ISSN :
0363-0269
eISSN :
1532-432X
Publisher :
Taylor & Francis, Philadelphia, United States - Pennsylvania
Livingstone FB. Malaria and human polymorphisms. Ann Rev Genet 1971; 5:33-38.
Modell B, Darlison M, Birgens H, Cario H, Faustino P, Giordano PC, Gulbis B, Hopmeier P, Lena-Russo D, Romao L, Theodorsson E. Epidemiology of haemoglobin disorders in Europe: an overview. Scand J Clin Lab Invest 2007; 67(1):39-69.
Davies SC, Cronin E, Gill M, Hickman M, Normand D. Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research. Health Technol Assess 2000; 4(3):1-99.
Bardakjian-Michau J. Neonatal detection of sickle cell disease. J Gynecol Obstet Biol Reprod (Paris) 2003; 32(Suppl 1):1S61-1S64.
Giordano PC, Harteveld CL. Prevention of hereditary haemoglobinopathies in The Netherlands. Ned Tijdschr Geneeskd 2006; 150(39):2137-2141.
Giordano PC, Plancke A, Van Meir CA, Janssen CA, Kok PJ, Van Rooijen-Nijdam IH, Tanis BC, van Huisseling JC, Versteegh FG. Carrier diagnostics and prevention of hemoglobinopathies in early pregnancy in The Netherlands: a pilot study. Prenat Diagn 2006; 26(8):719-724.
Giordano PC, Bouva MJ, Harteveld CL. A confidential inquiry estimating the number of patients affected with sickle cell disease and thalassemia major confirms the need for a prevention strategy in The Netherlands. Hemoglobin 2004; 28(4):287-296.
Gulbis B, Ferster A, Cotton F, Lebouchard MP, Cochaux P, Vertongen F. Neonatal haemoglobinopathy screening: review of a 10-year programme in Brussels. J Med Screen 2006; 13(2):76-78.
World Health Organization. The molecular genetic epidemiology of cystic fibrosis. Report of a joint meeting of WHO/ECFTN/ICF/(M)A/A/ECFS. Genoa, Italy, June 2002. WHO/HGN/CF/WG/04.02.
Badens C, North ML, Lena-Russo D. β Thalassemia in Metropolitan France. Press Med 2003; 32(22):1016-1021.
Giordano PC, Dihal AA, Harteveld CL. Estimating the attitude of immigrants toward primary prevention of the hemoglobinopathies. Prenat Diagn 2005; 25(10):885-893.